The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Subclonal evolution and cytogenetic aberrations in myeloma
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, briefly discusses subclonal evolution in multiple myeloma, and the importance of identifying high-risk cytogenetic markers at diagnosis. Dr Corre explains how gain of chromosome 1q (+1q) is better detected by single-cell analysis and the importance of identifying high-risk markers such as (+1q) or del(17p) at an earlier stage to improve patient prognosis. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
